Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.
Position: Sr. Biosample Manager
Nurix Therapeutics, Inc. is seeking a Sr. Biosample Manager to join the Clinical Operations team. This is an onsite role. This individual will work cross functionally, with both internal and external stakeholders, to plan, coordinate, and oversee all operational activities required to manage the lifecycle of the clinical biosamples and support translational research.
Responsibilities:
Study Management
Biosample and Vendor Management
Qualifications:
Salary Range: 140K - 180K plus equity and bonus
Nurix is an Equal Opportunity Employer offering a competitive salary and benefits package. Applicants should be legally entitled to work for any employer in the US.Nurix Therapeutics, Inc. is committed to protecting and respecting your privacy and personal information, including information collected by Nurix when you apply for a job with Nurix or in the course of your employment with Nurix. By applying for a position at Nurix, you agree to our collection and use of personal information as described in our Privacy Policy ( https://www.nurixtx.com/privacy-policy/).

Important Notice to Candidates: Nurix representatives with never conduct interviews by text and will never request personal financial information or ask candidates to purchase equipment.
At Nurix Therapeutics, we aim to fundamentally change the way disease is treated using degrader-based medicines. Our journey began with a vision to harness the power of the cell’s natural protein degradation machinery, the ubiquitin-proteasome system, to create a new class of therapeutics that can overcome the limitations of current treatments.